计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
L126490-5mg |
5mg |
现货 ![]() |
| |
L126490-10mg |
10mg |
现货 ![]() |
| |
L126490-50mg |
50mg |
期货 ![]() |
|
英文别名 | C23H25ClFN7O | 3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(3-methyl-1H-pyrazol-5-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine | AKOS037643413 | D10365 | D78334 | Gandotinib;3-(4-chloro-2-fluorobenzyl)-2-methyl-N-(3-methyl-1H-pyrazol-5-yl)-8-(morpho |
---|---|
规格或纯度 | Moligand™, ≥98% |
英文名称 | LY2784544 |
生化机理 | LY2784544 被确定为 JAK2 突变体 V617F 的高选择性抑制剂,已进入治疗多种骨髓增生性疾病的人体临床试验阶段。 |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
作用类型 | 抑制剂 |
作用机制 | 酪氨酸蛋白激酶 JAK2 抑制剂 |
产品介绍 |
LY2784544是一种有效的JAK2抑制剂,IC50为3 nM,作用于JAK2V617F有效,比作用于JAK1和JAK3选择性高8和20倍。Phase 2。A selective inhibitor of JAK2 mutant V617F. LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2. |
ALogP | 3.8 |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
分子类型 | 小分子 |
---|---|
IUPAC Name | 3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-amine |
INCHI | InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30) |
InChi Key | SQSZANZGUXWJEA-UHFFFAOYSA-N |
Canonical SMILES | CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F |
Isomeric SMILES | CC1=CC(=NN1)NC2=NN3C(=C(N=C3C(=C2)CN4CCOCC4)C)CC5=C(C=C(C=C5)Cl)F |
PubChem CID | 46213929 |
分子量 | 469.95 |
溶解性 | DMSO 94 mg/mL (200.02 mM); Water <1 mg/mL (<1 mM); Ethanol 9 mg/mL (19.15 mM) |
---|---|
分子量 | 469.900 g/mol |
XLogP3 | 3.800 |
氢键供体数Hydrogen Bond Donor Count | 2 |
氢键受体数Hydrogen Bond Acceptor Count | 7 |
可旋转键计数Rotatable Bond Count | 6 |
精确质量Exact Mass | 469.179 Da |
单同位素质量Monoisotopic Mass | 469.179 Da |
拓扑极表面积Topological Polar Surface Area | 83.400 Ų |
重原子数Heavy Atom Count | 33 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 644.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
Purity(HPLC) | 98-100(%) |
---|---|
Appearance(L126490) | White to off-white solid |
NMR spectrum | Conforms to Structure |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
批号(Lot Number) | 证书类型 | 日期 | 货号 |
---|---|---|---|
![]() |
分析证书 | 23-05-10 | L126490 |
1. Ma L, Clayton JR, Walgren RA, Zhao B, Evans RJ, Smith MC, Heinz-Taheny KM, Kreklau EL, Bloem L, Pitou C et al.. (2013) Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F.. Blood Cancer J, 3 (13): (e109). [PMID:23584399] [10.1021/op500134e] |
2. Berdeja J, Palandri F, Baer MR, Quick D, Kiladjian JJ, Martinelli G, Verma A, Hamid O, Walgren R, Pitou C et al.. (2018) Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.. Leuk Res, 71 (13): (82-88). [PMID:30025280] [10.1021/op500134e] |